New Onset Atrial Fibrillation
9
3
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
11.1%
1 terminated out of 9 trials
75.0%
-11.5% vs benchmark
56%
5 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in China
Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients
Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery
Tracking Atrial Fibrillation After Intensive Care Admission
Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery
Management of Paroxystic Atrial Fibrillation in French Intensive Care Units
Rapid Atrial Fibrillation Treatment Strategy
Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring
Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock